A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors

PRIMARY OBJECTIVES: I. To evaluate the safety and establish the recommended phase 2 dose (RP2D) of the doublet combination of copanlisib and olaparib and of the triplet combination of copanlisib, olaparib and MEDI4736 (durvalumab) in patients with molecularly-selected solid tumors. SECONDARY OBJECTI...

Full description

Bibliographic Details
Other Involved Persons: National Cancer Institute (NCI)
Format: eBook
Published: Bethesda (Maryland) : ClinicalTrials.gov December 10, 2019
Item Description:Copyright: Source: ClinicalTrials.gov (no modifications made)
Copyright: ClinicalTrials.gov processed this data on December 13, 2019
Copyright: Last update posted on ClinicalTrials.gov: December 10, 2019
Copyright: Last updated: 2019-12-16
Physical Description:Online-Ressource
QR Code: Show QR Code